 BioCardia, Inc. NASDAQ: BCDA, a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of three new patents for the companys technologies in the U.S., China and Japan. The new U.S. patent relates to the cell potency assay used in its CardiAMPTM Cell Therapy System, issued as U.S. Patent No: 10,520,505. The patent is for Methods of Measuring Potential for Therapeutic Potency and Defining Dosages for Autologous Cell Therapies. The Company also has European patent coverage for this technology. 